The global market for Data-Independent Acquisition (DIA) Quantitative Proteomics was valued at US$ 7554 million in the year 2023 and is projected to reach a revised size of US$ 14370 million by 2030, growing at a CAGR of 10.3% during the forecast period.
Data-Independent Acquisition (DIA) is a novel mass spectrometry data acquisition method developed in recent years. Current popular proteomics research techniques such as iTRAQ, TMT, Label-free, and SILAC utilize data-dependent acquisition (DDA), a method in which secondary mass spectrometry signals are collected based on the intensity of primary mass spectrometry signals. Stronger ion signals are selected for secondary acquisition, while weaker signals are discarded, resulting in the loss of secondary information from weak signals.DIA technology combines the high-throughput nature of traditional proteomics shotgun methods with the accurate quantification capabilities of the gold standard PRM (Parallel Reaction Monitoring) method. It was recognized by Nature Methods as a noteworthy technology in 2015. Presently, DIA quantitative proteomics includes two detection techniques: 3D DIA and 4D DIA. 3D DIA employs the Thermo Scientific QE series mass spectrometers, a classic choice for proteomics analysis due to its high peptide on-column loading capacity (ranging from 1-5 渭g of peptides). On the other hand, 4D DIA employs the TIMS TOF mass spectrometers from Bruker, which enhances sensitivity and detection capabilities compared to the classical 3D technology, resulting in higher protein and peptide detection yields from the same sample.Data-Independent Acquisition (DIA) proteomics technology is applicable to nearly all sample types, allowing unbiased collection of all information within samples. It offers a superior solution for achieving high coverage, accuracy, and in-depth analysis of proteomes. DIA is particularly well-suited for analyzing disease-related samples rich in biological information, providing a significant resource for biomarker discovery, molecular typing, disease mechanism investigation, and more. By comparing differences in protein composition among different groups or states, this approach enables systematic studies of diseases, facilitating the development of precision therapies.
North American market for Data-Independent Acquisition (DIA) Quantitative Proteomics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Data-Independent Acquisition (DIA) Quantitative Proteomics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Data-Independent Acquisition (DIA) Quantitative Proteomics in Medicine is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Data-Independent Acquisition (DIA) Quantitative Proteomics include Creative Dynamics Inc (Creative Proteomics), MtoZ-Biolabs Inc., CD Genomics, AxisPharm, BGI Genomics, Metware Biotechnology Inc (Metware), OBiO Technology ( Shanghai ) Corp.,Ltd., APPLIED PROTEIN TECHNOLOGY, Novogene, Biotech Pack, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Data-Independent Acquisition (DIA) Quantitative Proteomics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Data-Independent Acquisition (DIA) Quantitative Proteomics.
The Data-Independent Acquisition (DIA) Quantitative Proteomics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Data-Independent Acquisition (DIA) Quantitative Proteomics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Data-Independent Acquisition (DIA) Quantitative Proteomics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Creative Dynamics Inc (Creative Proteomics)
MtoZ-Biolabs Inc.
CD Genomics
AxisPharm
BGI Genomics
Metware Biotechnology Inc (Metware)
OBiO Technology ( Shanghai ) Corp.,Ltd.
APPLIED PROTEIN TECHNOLOGY
Novogene
Biotech Pack
SHANGHAI OE Biotech
ShangHai Biotree
JSR Corporation (Crown Bioscience)
Biomarker Technologies (BMK) GmbH
Aimsmass
Westlake Omics
WuHan RuiXing Biotechnology
GENECHEM
Wininnovate Biotechnology
Segment by Type
4D DIA
3D DIA
Segment by Application
Medicine
Plants
Animal Husbandry
Microbiology
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Data-Independent Acquisition (DIA) Quantitative Proteomics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 4D DIA
1.2.3 3D DIA
1.3 麻豆原创 by Application
1.3.1 Global Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Medicine
1.3.3 Plants
1.3.4 Animal Husbandry
1.3.5 Microbiology
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Perspective (2019-2030)
2.2 Global Data-Independent Acquisition (DIA) Quantitative Proteomics Growth Trends by Region
2.2.1 Global Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Data-Independent Acquisition (DIA) Quantitative Proteomics Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Data-Independent Acquisition (DIA) Quantitative Proteomics Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Dynamics
2.3.1 Data-Independent Acquisition (DIA) Quantitative Proteomics Industry Trends
2.3.2 Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Drivers
2.3.3 Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Challenges
2.3.4 Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Data-Independent Acquisition (DIA) Quantitative Proteomics Players by Revenue
3.1.1 Global Top Data-Independent Acquisition (DIA) Quantitative Proteomics Players by Revenue (2019-2024)
3.1.2 Global Data-Independent Acquisition (DIA) Quantitative Proteomics Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Data-Independent Acquisition (DIA) Quantitative Proteomics Revenue
3.4 Global Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Concentration Ratio
3.4.1 Global Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Data-Independent Acquisition (DIA) Quantitative Proteomics Revenue in 2023
3.5 Global Key Players of Data-Independent Acquisition (DIA) Quantitative Proteomics Head office and Area Served
3.6 Global Key Players of Data-Independent Acquisition (DIA) Quantitative Proteomics, Product and Application
3.7 Global Key Players of Data-Independent Acquisition (DIA) Quantitative Proteomics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Data-Independent Acquisition (DIA) Quantitative Proteomics Breakdown Data by Type
4.1 Global Data-Independent Acquisition (DIA) Quantitative Proteomics Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Data-Independent Acquisition (DIA) Quantitative Proteomics Forecasted 麻豆原创 Size by Type (2025-2030)
5 Data-Independent Acquisition (DIA) Quantitative Proteomics Breakdown Data by Application
5.1 Global Data-Independent Acquisition (DIA) Quantitative Proteomics Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Data-Independent Acquisition (DIA) Quantitative Proteomics Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size (2019-2030)
6.2 North America Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Country (2019-2024)
6.4 North America Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size (2019-2030)
7.2 Europe Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Country (2019-2024)
7.4 Europe Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size (2019-2030)
9.2 Latin America Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Data-Independent Acquisition (DIA) Quantitative Proteomics 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Creative Dynamics Inc (Creative Proteomics)
11.1.1 Creative Dynamics Inc (Creative Proteomics) Company Details
11.1.2 Creative Dynamics Inc (Creative Proteomics) Business Overview
11.1.3 Creative Dynamics Inc (Creative Proteomics) Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.1.4 Creative Dynamics Inc (Creative Proteomics) Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.1.5 Creative Dynamics Inc (Creative Proteomics) Recent Development
11.2 MtoZ-Biolabs Inc.
11.2.1 MtoZ-Biolabs Inc. Company Details
11.2.2 MtoZ-Biolabs Inc. Business Overview
11.2.3 MtoZ-Biolabs Inc. Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.2.4 MtoZ-Biolabs Inc. Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.2.5 MtoZ-Biolabs Inc. Recent Development
11.3 CD Genomics
11.3.1 CD Genomics Company Details
11.3.2 CD Genomics Business Overview
11.3.3 CD Genomics Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.3.4 CD Genomics Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.3.5 CD Genomics Recent Development
11.4 AxisPharm
11.4.1 AxisPharm Company Details
11.4.2 AxisPharm Business Overview
11.4.3 AxisPharm Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.4.4 AxisPharm Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.4.5 AxisPharm Recent Development
11.5 BGI Genomics
11.5.1 BGI Genomics Company Details
11.5.2 BGI Genomics Business Overview
11.5.3 BGI Genomics Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.5.4 BGI Genomics Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.5.5 BGI Genomics Recent Development
11.6 Metware Biotechnology Inc (Metware)
11.6.1 Metware Biotechnology Inc (Metware) Company Details
11.6.2 Metware Biotechnology Inc (Metware) Business Overview
11.6.3 Metware Biotechnology Inc (Metware) Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.6.4 Metware Biotechnology Inc (Metware) Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.6.5 Metware Biotechnology Inc (Metware) Recent Development
11.7 OBiO Technology ( Shanghai ) Corp.,Ltd.
11.7.1 OBiO Technology ( Shanghai ) Corp.,Ltd. Company Details
11.7.2 OBiO Technology ( Shanghai ) Corp.,Ltd. Business Overview
11.7.3 OBiO Technology ( Shanghai ) Corp.,Ltd. Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.7.4 OBiO Technology ( Shanghai ) Corp.,Ltd. Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.7.5 OBiO Technology ( Shanghai ) Corp.,Ltd. Recent Development
11.8 APPLIED PROTEIN TECHNOLOGY
11.8.1 APPLIED PROTEIN TECHNOLOGY Company Details
11.8.2 APPLIED PROTEIN TECHNOLOGY Business Overview
11.8.3 APPLIED PROTEIN TECHNOLOGY Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.8.4 APPLIED PROTEIN TECHNOLOGY Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.8.5 APPLIED PROTEIN TECHNOLOGY Recent Development
11.9 Novogene
11.9.1 Novogene Company Details
11.9.2 Novogene Business Overview
11.9.3 Novogene Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.9.4 Novogene Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.9.5 Novogene Recent Development
11.10 Biotech Pack
11.10.1 Biotech Pack Company Details
11.10.2 Biotech Pack Business Overview
11.10.3 Biotech Pack Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.10.4 Biotech Pack Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.10.5 Biotech Pack Recent Development
11.11 SHANGHAI OE Biotech
11.11.1 SHANGHAI OE Biotech Company Details
11.11.2 SHANGHAI OE Biotech Business Overview
11.11.3 SHANGHAI OE Biotech Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.11.4 SHANGHAI OE Biotech Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.11.5 SHANGHAI OE Biotech Recent Development
11.12 ShangHai Biotree
11.12.1 ShangHai Biotree Company Details
11.12.2 ShangHai Biotree Business Overview
11.12.3 ShangHai Biotree Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.12.4 ShangHai Biotree Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.12.5 ShangHai Biotree Recent Development
11.13 JSR Corporation (Crown Bioscience)
11.13.1 JSR Corporation (Crown Bioscience) Company Details
11.13.2 JSR Corporation (Crown Bioscience) Business Overview
11.13.3 JSR Corporation (Crown Bioscience) Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.13.4 JSR Corporation (Crown Bioscience) Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.13.5 JSR Corporation (Crown Bioscience) Recent Development
11.14 Biomarker Technologies (BMK) GmbH
11.14.1 Biomarker Technologies (BMK) GmbH Company Details
11.14.2 Biomarker Technologies (BMK) GmbH Business Overview
11.14.3 Biomarker Technologies (BMK) GmbH Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.14.4 Biomarker Technologies (BMK) GmbH Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.14.5 Biomarker Technologies (BMK) GmbH Recent Development
11.15 Aimsmass
11.15.1 Aimsmass Company Details
11.15.2 Aimsmass Business Overview
11.15.3 Aimsmass Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.15.4 Aimsmass Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.15.5 Aimsmass Recent Development
11.16 Westlake Omics
11.16.1 Westlake Omics Company Details
11.16.2 Westlake Omics Business Overview
11.16.3 Westlake Omics Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.16.4 Westlake Omics Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.16.5 Westlake Omics Recent Development
11.17 WuHan RuiXing Biotechnology
11.17.1 WuHan RuiXing Biotechnology Company Details
11.17.2 WuHan RuiXing Biotechnology Business Overview
11.17.3 WuHan RuiXing Biotechnology Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.17.4 WuHan RuiXing Biotechnology Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.17.5 WuHan RuiXing Biotechnology Recent Development
11.18 GENECHEM
11.18.1 GENECHEM Company Details
11.18.2 GENECHEM Business Overview
11.18.3 GENECHEM Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.18.4 GENECHEM Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.18.5 GENECHEM Recent Development
11.19 Wininnovate Biotechnology
11.19.1 Wininnovate Biotechnology Company Details
11.19.2 Wininnovate Biotechnology Business Overview
11.19.3 Wininnovate Biotechnology Data-Independent Acquisition (DIA) Quantitative Proteomics Introduction
11.19.4 Wininnovate Biotechnology Revenue in Data-Independent Acquisition (DIA) Quantitative Proteomics Business (2019-2024)
11.19.5 Wininnovate Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Creative Dynamics Inc (Creative Proteomics)
MtoZ-Biolabs Inc.
CD Genomics
AxisPharm
BGI Genomics
Metware Biotechnology Inc (Metware)
OBiO Technology ( Shanghai ) Corp.,Ltd.
APPLIED PROTEIN TECHNOLOGY
Novogene
Biotech Pack
SHANGHAI OE Biotech
ShangHai Biotree
JSR Corporation (Crown Bioscience)
Biomarker Technologies (BMK) GmbH
Aimsmass
Westlake Omics
WuHan RuiXing Biotechnology
GENECHEM
Wininnovate Biotechnology
听
听
*If Applicable.
